BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aug. 1, 2006--Enzon Pharmaceuticals, Inc. (Nasdaq:ENZN) (Enzon or the Company) today announced its financial results for the second quarter of 2006. For the three months ended June 30, 2006, Enzon reported net income of $11.0 million or $0.25 per diluted share, as compared to a net loss of $(85.5) million or $(1.97) per diluted share for the three months ended June 30, 2005.
